
Kimmie Ng
Gastrointestinal oncologist and founding director of the Young-Onset Colorectal Cancer Center at Dana-Farber, and professor of medicine at Harvard Medical School; interviewed about rising rates of young-onset cancers.
Top 3 podcasts with Kimmie Ng
Ranked by the Snipd community

30 snips
Jul 17, 2025 • 25min
Early-Onset Gastrointestinal Cancers
In this discussion, Kimmie Ng, Associate Chief of Gastrointestinal Oncology at Dana-Farber Cancer Institute, reveals alarming trends in early-onset gastrointestinal cancers, particularly in patients under 50. She highlights the importance of recognizing modifiable risk factors like obesity and the psychological challenges young patients endure. The conversation also touches on updated screening guidelines for colorectal cancer and the role of Helicobacter pylori in esophagogastric cancers, emphasizing the urgent need for better diagnostic strategies.

15 snips
Oct 10, 2025 • 29min
Why Are So Many Young People Getting Cancer?
Dr. Kimmie Ng, a leading gastrointestinal oncologist and founding director of the Young-Onset Colorectal Cancer Center at Dana-Farber, discusses alarming trends in cancer diagnoses among young adults. She outlines how prevalence is soaring, particularly with colorectal cancer, and attributes some causes to lifestyle, genetics, and early-life exposures. Ng emphasizes the importance of screening, identifying red flags, and breaking stigma around bowel health, while advocating for tailored prevention strategies.

15 snips
Jun 27, 2025 • 20min
Clinical Highlights From ASCO 2025
Kimmie Ng, MD, MPH, is an associate editor at JAMA and leads the Division of Gastrointestinal Oncology at Dana-Farber. She shares groundbreaking insights from ASCO's annual meeting, including how intensive exercise can boost survival rates in advanced colon cancer patients. Ng highlights the significant link between diet, exercise, and cancer outcomes, as well as findings on GLP-1 receptor agonists reducing colorectal cancer risk. Additionally, she discusses innovations in cancer screening and critiques traditional clinical trial metrics, advocating for patient-centered outcomes.


